ZFN genetically engineered HSC therapy (Sangamo/University College London)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameZFN genetically engineered HSC therapy (Sangamo/University College London)
Drug Alias Namezinc finger nuclease gene-repaired hematopoietic stem cell therapy (Sangamo Biosciences/University College London)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapyCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSevere Combined Immunodeficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity College LondonSangamo Therapeutics IncKing'S College London
Active IndicationsN/A
Inactive IndicationsSevere Combined Immunodeficiency

Other Information

ATC CodeN/A
Related LinksN/A